Here are seven insights:
1. Integra LifeSciences' offered a price of $1.05 billion in cash.
2. The Codman Neurosurgery portfolio includes devices for hydrocephalus, neuro-critical care and operative neurosurgery.
3. Integra hopes to combine Codman's neurosurgery portfolio with its tissue ablation, dural repair and cranial stabilization products to offer a comprehensive neurosurgery portfolio.
4. In 2016, the Codman neurosurgery products generated about $370 million in revenue.
5. Integra anticipates the transaction to be accretive to adjusted earnings-per-share by $0.22 at least in the first full year post-closing.
6. While Integra expects the Codman Neurosurgery revenue to see some disruption in the first year after acquisition, the company believes it will increase 3 percent to 6 percent in the longer term.
7. After the information and consultation process with the employees' representatives in other countries concludes, Integra plans to enter into a definitive purchase and sale agreement.
More articles on devices:
FDA grants Medtronic expanded indication for cancer-fighting OsteoCool Ablation System — 7 takeaways
FDA clears Centric Medical's Metatarsal Hemi Implant System — 5 details
3-D printing for medical sector to grow at 11.7% CAGR through 2024: 5 notes